Garland, Suzanne M.Brotherton, J. M. L.Moscicki, Anna-BarbaraKaufmann, A. M.Stanley, MargaretBhatla, N.Sankaranarayanan, RengaswamySanjosé Llongueras, Silvia dePalefsky, Joel2018-07-272018-07-272017-12-01https://hdl.handle.net/2445/124030It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.4 p.application/pdfengcc by-nc-nd (c) Garland et al., 2017http://creativecommons.org/licenses/by-nc-nd/3.0/es/Vacuna del papil·lomavirusPapillomavirus vaccinesinfo:eu-repo/semantics/article2018-07-24info:eu-repo/semantics/openAccess29179867